| Prev Close | 13.53 |
| Open | 13.50 |
| Day Low/High | 13.13 / 13.59 |
| 52 Wk Low/High | 11.83 / 33.44 |
| Volume | 478.05K |
| Avg Volume | 699.70K |
Biotech Stock Mailbag: GTx, Vanda, Pharmacyclics
Biotech columnist Adam Feuerstein answers readers' questions about health care companies.
5 Stocks Setting Up to Break Out
These stocks look ready to break out and trade higher from current levels.
Law Offices Of Todd M. Garber Announces Investigation Of Vanda Pharmaceuticals, Inc.
The Law Offices of Todd M. Garber announces that it is investigating potential claims against Vanda Pharmaceuticals, Inc.
Vanda Pharmaceuticals Shareholder Alert: Briscoe Law And Powers Taylor Investigate Possible Breaches Of Fiduciary Duty By Officers And Directors
Former United States Securities and Exchange Commission attorney Willie Briscoe, founder of The Briscoe Law Firm, PLLC, and the securities litigation firm of Powers Taylor, LLP announce that a federal class action...
Best And Worst Performing Biotech Stocks In the Second Quarter
Clovis Oncology and Stemline Therapeutics were among the best-performing biotech stocks in the June quarter.
Washington, DC Law Firm Finkelstein Thompson LLP Investigates Vanda Pharmaceuticals, Inc.
Shareholder law firm Finkelstein Thompson LLP is investigating potential claims on behalf of shareholders of Vanda Pharmaceuticals, Inc.
Biotech Stock Mailbag: PTC Therapeutics, Vanda, MannKind
Biotech columnist Adam Feuerstein answers readers' questions about healthcare companies.
SHAREHOLDER ALERT: The Law Firm Of Levi & Korsinsky, LLP Launches An Investigation Into Possible Breaches Of Fiduciary Duty By Vanda Pharmaceuticals, Inc.
Levi & Korsinsky is investigating potential claims on behalf of purchasers of Vanda Pharmaceuticals, Inc.
Law Firm Of Wohl & Fruchter LLP Announces Investigation Of Vanda Pharmaceuticals, Inc.
The law firm of Wohl & Fruchter LLP announces that it is investigating possible violations of federal securities laws by officers and directors of Vanda Pharmaceuticals, Inc.
Stock Futures Waver as Investors Go On Bernanke-Watch
Stock futures are wavering Wednesday as investors eagerly await the conclusion of the two-day Federal Reserve meeting.
Vanda's Sleep Disorder Drug Is A Nightmare
FDA approval of tasimelteon is unlikely because Vanda changed the study design and mis-enrolled patients.
Raise Cash Ahead of Fed News
The market could take off on a bullish surprise, but binary events are always tough to trade.
Commit To Purchase Vanda Pharmaceuticals At $7, Earn 21.1% Annualized
Investors eyeing a purchase of Vanda Pharmaceuticals Inc shares, but cautious about paying the going market price of $9.27/share, might benefit from considering selling puts among the alternative strategies at their disposal. One interesting put contract in particular, is the December put at the $7 strike, which has a bid at the time of this writing of 80 cents.
Biotech Stock Mailbag: Amarin
Biotech columnist Adam Feuerstein answers readers' questions about health-care companies.
Vanda Pharmaceuticals Inc. Stock Downgraded (VNDA)
Vanda Pharmaceuticals (Nasdaq:VNDA) has been downgraded by TheStreet Ratings from from a hold to sell.
Biotech Stock Mailbag: Exelixis
Biotech columnist Adam Feuerstein answers readers' questions and concerns about health care and drug-related stocks.
5 Stocks Setting Up to Break Out
These stocks look poised to break out and trade significantly higher from current levels.
Biotech Stock Mailbag: Bio-Hazards
Biotech columnist Adam Feuerstein answers readers' questions and concerns about health care and drug-related stocks.
Vanda Pharmaceuticals Inc. Stock Upgraded By TheStreet Ratings (VNDA)
Vanda Pharmaceuticals (Nasdaq:VNDA) has been upgraded by TheStreet Ratings from a sell to hold.
Vanda's Fanapt Falls Flat
Vanda's schizophrenia drug closes 2010 with just $31 million in sales, far below expectations.
Clinical Data: Bulls and Bears Round Two
Clinical Data's new antidepressant is approved but bulls want the company to be sold for an even higher premium while bears say any deal is unlikely.
10 Unloved Stocks to Rise Up to 120%
These five-star stocks trade at huge discounts to fair value and could soar in 2011.
Biotech Stock Mailbag - Titan Pharma
Biotech columnist Adam Feuerstein answers readers' questions about drug and health care-related firms.
Biotech Stock Mailbag: Exact Sciences
Biotech columnist Adam Feuerstein answers readers' questions about drug and health care-related firms.
Biotech Stock Mailbag: Avanir Pharma
Biotech columnist Adam Feuerstein answers readers' questions about drug and health care-related firms.
Biotech Stock Mailbag - 2Q Updates
Biotech columnist Adam Feuerstein answers readers' questions about drug and health care-related firms.
Biotech Stock Mailbag: Amarin Pharma
Biotech columnist Adam Feuerstein answers readers' questions and concerns about healthcare and drug-related stocks.
Vanda Schizophrenia Drug Gets Rotten Review
Vanda's Fanapt is treated roughly in the new psychiatrists' 'bible', further hurting the drug's launch efforts.
Biotech Calendar: Key Dates for May
Here's a list of May's potentially stock-moving biotech events.
